Literature DB >> 18358727

Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor.

Oleg Khorev1, Daniela Stokmaier, Oliver Schwardt, Brian Cutting, Beat Ernst.   

Abstract

A series of novel, fluorescent ligands designed to bind with high affinity and specificity to the asialoglycoprotein receptor (ASGP-R) has been synthesized and tested on human liver cells. The compounds bear three non-reducing, beta-linked Gal or GalNAc moieties linked to flexible spacers for an optimal spatial interaction with the binding site of the ASGP-R. The final constructs were selectively endocytosed by HepG2 cells derived from parenchymal liver cells-the major human liver cell type-in a process that was visualized with the aid of fluorescence microscopy. Furthermore, the internalization was analyzed with flow cytometry, which showed the process to be receptor-mediated and selective. The compounds described in this work could serve as valuable tools for studying hepatic endocytosis, and are suited as carriers for site-specific drug delivery to the liver.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18358727     DOI: 10.1016/j.bmc.2008.03.017

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  32 in total

Review 1.  Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.

Authors:  Alexandre J Debacker; Jon Voutila; Matthew Catley; David Blakey; Nagy Habib
Journal:  Mol Ther       Date:  2020-06-17       Impact factor: 11.454

Review 2.  Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides.

Authors:  R L Juliano; K Carver; C Cao; X Ming
Journal:  J Drug Target       Date:  2012-11-19       Impact factor: 5.121

3.  Development of siRNA Therapeutics for the Treatment of Liver Diseases.

Authors:  Anja Holm; Marianne Bengtson Løvendorf; Sakari Kauppinen
Journal:  Methods Mol Biol       Date:  2021

4.  Epitope structure of the carbohydrate recognition domain of asialoglycoprotein receptor to a monoclonal antibody revealed by high-resolution proteolytic excision mass spectrometry.

Authors:  Raluca Stefanescu; Rita Born; Adrian Moise; Beat Ernst; Michael Przybylski
Journal:  J Am Soc Mass Spectrom       Date:  2011-01-20       Impact factor: 3.109

5.  Efficient Liver Targeting by Polyvalent Display of a Compact Ligand for the Asialoglycoprotein Receptor.

Authors:  Carlos A Sanhueza; Michael M Baksh; Benjamin Thuma; Marc D Roy; Sanjay Dutta; Cathy Préville; Boris A Chrunyk; Kevin Beaumont; Robert Dullea; Mark Ammirati; Shenping Liu; David Gebhard; James E Finley; Christopher T Salatto; Amanda King-Ahmad; Ingrid Stock; Karen Atkinson; Benjamin Reidich; Wen Lin; Rajesh Kumar; Meihua Tu; Elnaz Menhaji-Klotz; David A Price; Spiros Liras; M G Finn; Vincent Mascitti
Journal:  J Am Chem Soc       Date:  2017-02-23       Impact factor: 15.419

Review 6.  Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.

Authors:  Pedro Renato de Paula Brandão; Simoneide S Titze-de-Almeida; Ricardo Titze-de-Almeida
Journal:  Mol Diagn Ther       Date:  2020-02       Impact factor: 4.074

7.  Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing.

Authors:  Romain Rouet; Benjamin A Thuma; Marc D Roy; Nathanael G Lintner; David M Rubitski; James E Finley; Hanna M Wisniewska; Rima Mendonsa; Ariana Hirsh; Lorena de Oñate; Joan Compte Barrón; Thomas J McLellan; Justin Bellenger; Xidong Feng; Alison Varghese; Boris A Chrunyk; Kris Borzilleri; Kevin D Hesp; Kaihong Zhou; Nannan Ma; Meihua Tu; Robert Dullea; Kim F McClure; Ross C Wilson; Spiros Liras; Vincent Mascitti; Jennifer A Doudna
Journal:  J Am Chem Soc       Date:  2018-05-18       Impact factor: 15.419

Review 8.  Oligonucleotide conjugates for therapeutic applications.

Authors:  Johannes Winkler
Journal:  Ther Deliv       Date:  2013-07

9.  Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance.

Authors:  Hongzhi Wang; Satheesh Ellipilli; Wen-Jui Lee; Xin Li; Mario Vieweger; Yuan-Soon Ho; Peixuan Guo
Journal:  J Control Release       Date:  2020-12-13       Impact factor: 9.776

10.  Receptor-mediated endocytosis and brain delivery of therapeutic biologics.

Authors:  Guangqing Xiao; Liang-Shang Gan
Journal:  Int J Cell Biol       Date:  2013-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.